This raises the possibility of treatments that upregulate or restore AQP1 expression in aged humans, whose CFS turnover is damaged by Alzheimer’s disease or normal pressure hydrocephalus [84, 85], by applying an opposite therapy to the one used to manage hydrocephalus. The gene discussed is AQP1; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.